Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 211 to 220 of 596 total matches.
Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
for treatment of
idiopathic hypersomnia in adults. It is the first drug
to be approved ...
Xywav (Jazz), an oral solution that contains calcium,
magnesium, potassium, and sodium oxybates, has
been approved by the FDA for treatment of idiopathic
hypersomnia in adults. It is the first drug to be
approved in the US for this indication. Xywav was
approved in 2020 for treatment of excessive daytime
sleepiness or cataplexy in patients ≥7 years old with
narcolepsy. It contains about 92% less sodium than
sodium oxybate oral solution (Xyrem), which has
been available in the US for years for use in patients
≥7 years old with narcolepsy.
In Brief: OTC Ivermectin for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
option that has been effective for treatment of head
lice resistant to topical drugs.4
MECHANISM ...
Topical ivermectin lotion 0.5% (Sklice, and generics),
which has been available by prescription since 2012,
is now FDA-approved for sale over the counter (OTC)
for treatment of head lice in patients ≥6 months old.
Ivermectin is also available by prescription as a 1%
cream (Soolantra) approved for topical treatment of
inflammatory lesions of rosacea and in oral tablets
(Stromectol, and generics) for treatment of various
parasitic infections.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):103-4 doi:10.58347/tml.2023.1679e | Show Introduction Hide Introduction
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
or meaning; such
suffixes are added to biologic drugs to distinguish reference products ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
to
either drug. Oral cabotegravir (Vocabria) was also
approved by the FDA for use in combination with
oral ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
)
can be tried (see Table 3).3 All of these drugs have
been modestly effective in reducing abdominal ...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
An EUA for Baricitinib (Olumiant) for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
in combination with the IV antiviral drug remdesivir
(Veklury).1 Baricitinib has been available for treatment ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be used
in combination with the IV antiviral drug remdesivir
(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in...
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
; also
called Berger's disease) who are at risk of rapid
disease progression. It is the first drug ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger's disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.
Nalmefene Returns for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
glucuronidation
Elimination Primarily in urine
Half-life 10.8 hours
Table 2. Some Drugs for Reversal of Opioid ...
The FDA has approved a generic injectable formulation
of the opioid antagonist nalmefene (Purdue) for the
management of known or suspected opioid overdose.
Revex, the reference product, was withdrawn from the
market in 2008 for commercial reasons.
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
was based on data demonstrating that the drug is
safe and effective for use as directed in the labeling ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Lotilaner (Xdemvy) for Demodex Blepharitis
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
of Demodex blepharitis. Lotilaner is the first
drug to be approved in the US for this indication.
Table 1 ...
The FDA has approved a 0.25% ophthalmic solution
of the ectoparasiticide lotilaner (Xdemvy – Tarsus) for
treatment of Demodex blepharitis. Lotilaner is the first
drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):99-100 doi:10.58347/tml.2024.1705b | Show Introduction Hide Introduction